NOT FOR DISTRIBUTION IN THE UNITED STATES
Zur Rose Group AG increases public bond to CHF 115 million
Due to strong demand, Zur Rose Group AG announces today an increase of CHF 30 million of the public bond launched on 22 June 2018, bringing the new total outstanding amount to CHF 115 million. The final conditions are as follows:
Issuer Zur Rose Group AG
Issue amount CHF 30 million (new total size CHF 115 million)
Interest rate (coupon) 2.50% p.a.
Term to maturity 5 years
Issue price 100.20%
Repayment price 100%
Settlement 19 July 2018
Listing The listing of the bonds on the SIX Swiss Exchange has been applied for
ISIN CH0426621691 (fungible as of settlement date with ISIN CH0421460442)
As previously communicated, the proceeds of the bond will be used by the issuer primarily to finance acquisitions and for general corporate purposes.
A syndicate of banks, under the lead of UBS AG as sole bookrunner, Raiffeisen as joint lead manager and Bank Vontobel as co-manager, accompanies the issuance of the public bond.
Marcel Ziwica, Chief Financial Officer
e-mail: firstname.lastname@example.org, telephone: +41 58 810 11 49
15 August 2018 Half-year report (analyst and media conference)
24 October 2018 Q3 Trading Update
Zur Rose Group
Operating under the Zur Rose and DocMorris brands, the Swiss-based Zur Rose Group is Europe's leading online pharmacy and one of Switzerland's foremost wholesale suppliers to medical doctors. Through its business model, it helps to ensure safe, reliable and high-quality pharmaceutical care, while also excelling in developing innovative medicines management services to increase the effectiveness of the medication process. This creation of added value, the strong focus on patients and the commitment to supply medication at low cost for the benefit of payors and patients make the Group an important strategic partner for all healthcare stakeholders.
The Zur Rose Group is headquartered in Frauenfeld, from where it also serves the Swiss market. Customers in Germany and Austria are primarily supplied from Heerlen (NL). Furthermore, the Group holds a majority interest in BlueCare in Winterthur, the leading provider of networking systems in the Swiss healthcare market. Employing more than 1000 people at its various locations, Zur Rose Group generated revenue of CHF 983 million in 2017. Zur Rose Group AG's shares (ticker symbol ROSE, Swiss security no. 4261528, ISIN CH0042615283) are traded on SIX Swiss Exchange. More information at zurrosegroup.com.
THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. IN PARTICULAR, THIS INFORMATION IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. ANY NON-COMPLIANCE WITH SUCH RESTRICTIONS MAY RESULT IN AN INFRINGEMENT OF U.S. SECURITIES LAWS. SECURITIES OF ZUR ROSE AG ("COMPANY") ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF THE COMPANY HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO OR FOR THE ACCOUNT OF U.S. PERSONS EXCEPT IN AN "OFFSHORE TRANSACTION" IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT. THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO ART. 652A OR ART. 1156 OF THE SWISS CODE OF OBLIGATIONS OR ART. 27 ET SEQ. OF THE SIX SWISS EXCHANGE LISTING RULES.